In January, 2021 the manufacturer of Tepezza announced a short-term supply disruption. Tepezza is now available again, and the Infusion Center of Pennsylvania is among the first centers in the nation to resume treatments.
The Infusion Center of Pennsylvania infuses Tepezza!
Tepezza (teprotumumab-trbw) is an insulin-like growth factor-1 receptor inhibitor used to treat Thyroid Eye Disease, an autoimmune disease characterized by proptosis (a condition where the eyes are pushed forward and bulge outward) leading to eye pain double vision and difficulty closing the eyelid.
ICPA participated in clinical trials of Tepezza and began administering the drug on the first day it was commercially available in March, 2020.
Co-pay assistance may be available to qualifying patients. Visit the Tepezzza Co-pay Assistance website or contact us at (610) 495-6800.
Growth hormone receptor blockers
Thyroid Eye Disease (TED)
Once every 3 weeks for 8 doses
About 90 minutes